Marek Poszepczynski, joint lead investment manager of International Biotechnology Trust comments:
“There are a number of companies working to address mental health, which remains a high unmet medical need. For disease areas such as schizophrenia and major depression, there is an increased focus upon mental health especially after the impact of the pandemic and lockdowns.
“Looking at companies in IBT’s portfolio, Sage Therapeutics and Intra-Cellular Therapies are two examples of such companies that have candidate treatments for mental health diseases. The former is set to read out phase 3 trials in major depression imminently. Intra-Cellular has recently received approval for Caplyta, a treatment for negative symptoms of schizophrenia and the drug is in late stage trials to investigate its effect in major depression. Unlike oncology, for example, mental health therapeutics have not had the same pace of scientific breakthroughs but these two companies are bucking the trend with their potential treatments.“
